Urologists Explore Laws Affecting Male Infertility Treatment and the First Nonhormonal Hydrogel-Based Male Contraceptive

• Arshia Sandozi, DO, from Maimonides Medical Center, found health insurance coverage for the diagnosis and treatment of infertility is highly variable and continues to be a barrier faced by patients desiring to conceive. ”Disparities in Infertility Coverage in the United States.”
• James Dupree, MD, from University of Michigan, evaluated the use of in-vitro fertilization and three common male infertility procedures; varicocelectomy, testicular/epididymal biopsy, and vasectomy reversal in three groups of states. “Impact of State In-Vitro Fertilization Mandates on Male Infertility Care.”
• Nathan Lawrentschuk, MBBS, from University of Melbourne Department of Surgery, presented the initial results from a first in human clinical trial of ADAM. “Preliminary Results of a First in Human Dose-Ranging Clinical Trial of ADAM®, a Nonhormonal Hydrogel-Based Male Contraceptive.”

“We have outstanding research being presented at this year’s meeting in the area of male fertility and contraception, ranging from novel contraceptive therapeutics to important health policy studies of state insurance mandates for fertility coverage,” said Dr. Halpern. “This is an exciting time for our field."